Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Interest & Investment Income (2023 - 2026)

Denali Therapeutics has reported Interest & Investment Income over the past 3 years, most recently at $8.9 million for Q4 2025.

  • Quarterly Interest & Investment Income fell 41.18% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.9 million through Dec 2025, down 33.62% year-over-year, with the annual reading at $42.9 million for FY2025, 33.62% down from the prior year.
  • Interest & Investment Income was $8.9 million for Q4 2025 at Denali Therapeutics, down from $10.5 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $17.6 million in Q2 2024 and troughed at $8.9 million in Q4 2025.
  • The 3-year median for Interest & Investment Income is $13.0 million (2023), against an average of $13.3 million.
  • Year-over-year, Interest & Investment Income surged 44.22% in 2024 and then tumbled 41.18% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $13.1 million in 2023, then grew by 15.48% to $15.2 million in 2024, then tumbled by 41.18% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Interest & Investment Income are $8.9 million (Q4 2025), $10.5 million (Q3 2025), and $10.8 million (Q2 2025).